effect of atorvastatin and rosuvastatin in acute ischemic stroke patients

Phase 2

Recruiting

• Conditions: Acute ischemic stroke.; Cerebral infarction

• Registration Number: IRCT20181009041286N2
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with acute brain ischemic stroke
Referral in the first 24 hours after the onset of symptoms
No recent history of statin use

Exclusion Criteria

Past history of autoimmune disease or rheumatology diseases
Recent drug history of antineoplastic or anti-inflammatory
Past history of statin's hypersensivity

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TNF alpha. Timepoint: before intervention and the fifth day after intervention. Method of measurement: TNF alpha willbe assay by ELISA.;ESR 1 hour. Timepoint: before intervention and the fifth day after intervention. Method of measurement: Wintrobe method.;C-reactive protein (CRP). Timepoint: before intervention and the fifth day after intervention. Method of measurement: Immunoturbidimetry.

Secondary Outcome Measures

Name	Time	Method
IHSS: The National Institutes of Health Stroke Scale. Timepoint: before intervention and the fifth day after intervention. Method of measurement: The National Institutes of Health Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment.;The Modified Rankin Scale (mRS) measures degree of disability/dependence after a stroke. Timepoint: before intervention and the fifth day after intervention. Method of measurement: a questionnaire used by healthcare providers.